Rapid kVp switching dual-energy CT in the assessment of urolithiasis in patients with large body habitus: preliminary observations on image quality and stone characterization

Abdominal Radiology - The purpose of this study was to investigate the image quality (IQ) considerations of rapid kVp switching dual-energy CT (rsDECT) in the assessment of urolithiasis in patients...     

Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer

Background

Patients with advanced cancer often experience muscle wasting (sarcopenia), yet little is known about the characteristics associated with sarcopenia and the relationship between sarcopenia and patients’ quality of life (QOL) and mood.

Materials and Methods

As part of a randomized trial, we assessed baseline QOL (Functional Assessment of Cancer Therapy‐General [FACT‐G]) and mood (Hospital Anxiety and Depression Scale [HADS]) in patients within 8 weeks of diagnosis of incurable lung or gastrointestinal cancer, and prior to randomization. Using computed tomography scans collected as part of routine clinical care, we assessed sarcopenia at the level of the third lumbar vertebra with validated sex‐specific cutoffs. We used logistic regression to explore characteristics associated with presence of sarcopenia. To examine associations between sarcopenia, QOL and mood, we used linear regression, adjusted for patients’ age, sex, marital status, education, and cancer type.

Results

Of 237 participants (mean age = 64.41 ± 10.93 years), the majority were male (54.0%) and married (70.5%) and had lung cancer (56.5%). Over half had sarcopenia (55.3%). Older age (odds ratio [OR] = 1.05, p = .002) and education beyond high school (OR = 1.95, p = .047) were associated with greater likelihood of having sarcopenia, while female sex (OR = 0.25, p < .001) and higher body mass index (OR = 0.79, p < .001) correlated with lower likelihood of sarcopenia. Sarcopenia was associated with worse QOL (FACT‐G: B = ?4.26, p = .048) and greater depression symptoms (HADS‐depression: B = ?1.56, p = .005).

Conclusion

Sarcopenia was highly prevalent among patients with newly diagnosed, incurable cancer. The associations of sarcopenia with worse QOL and depression symptoms highlight the need to address the issue of sarcopenia early in the course of illness.

Implications for Practice

This study found that sarcopenia, assessed using computed tomography scans acquired as part of routine clinical care, is highly prevalent in patients with newly diagnosed, incurable cancer. Notably, patients with sarcopenia reported worse quality of life and greater depression symptoms than those without sarcopenia. These findings highlight the importance of addressing muscle loss early in the course of illness among patients with incurable cancer. In the future, investigators should expand upon these findings to develop strategies for assessing and treating sarcopenia while striving to enhance the quality of life and mood outcomes of patients with advanced cancer.     

Utility of positron emission tomography/CT in the evaluation of small bowel pathology

We describe the management principles and different roles of positron emission tomography (PET)/CT in the evaluation of patients with small bowel tumours (adenocarcinoma, gastrointestinal stromal tumour, lymphoma, metastases) from initial staging, monitoring response to treatment, to detection of recurrent disease. We also discuss the various non-malignant aetiologies of small bowel fludeoxyglucose (FDG) PET uptake, and other pitfalls in FDG PET/CT interpretation. Awareness of the imaging appearances of small bowel tumours, patterns of disease spread and potential PET/CT interpretation pitfalls are of paramount importance to optimise diagnostic accuracy.     

Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions

Hepatocellular carcinoma(HCC) is a leading cause of morbidity and mortality worldwide, with rising clinical and economic burden as incidence increases. Thereare a multitude of evolving treatment options, including locoregional therapies which can be used alone, in combination with each other, or in combination with systemic therapy. These treatment options have shown to be effective in achieving remission, controlling tumor progression, improving disease free and overall survival in patients who cannot undergo resection and providing a bridge to transplant by debulking tumor burden to downstage patients. Following locoregional therapy(LRT), it is crucial to provide treatment response assessment to guide management and liver transplant candidacy. Therefore, Liver Imaging Reporting and Data Systems(LI-RADS) Treatment Response Algorithm(TRA) was created to provide a standardized assessment of HCC following LRT. LIRADS TRA provides a step by step approach to evaluate each lesion independently for accurate tumor assessment. In this review, we provide an overview of different locoregional therapies for HCC, describe the expected post treatment imaging appearance following treatment, and review the LI-RADS TRA with guidance for its application in clinical practice. Unique to other publications, we will also review emerging literature supporting the use of LI-RADS for assessment of HCC treatment response after LRT.     

Low-dose whole-body CT using deep learning image reconstruction: image quality and lesion detection

Objectives:To evaluate image quality and lesion detection capabilities of low-dose (LD) portal venous phase whole-body computed tomography (CT) using deep learning image reconstruction (DLIR).Methods:The study cohort of 59 consecutive patients (mean age, 67.2 years) who underwent whole-body LD CT and a prior standard-dose (SD) CT reconstructed with hybrid iterative reconstruction (SD-IR) within one year for surveillance of malignancy were assessed. The LD CT images were reconstructed with hybrid iterative reconstruction of 40% (LD-IR) and DLIR (LD-DLIR). The radiologists independently evaluated image quality (5-point scale) and lesion detection. Attenuation values in Hounsfield units (HU) of the liver, pancreas, spleen, abdominal aorta, and portal vein; the background noise and signal-to-noise ratio (SNR) of the liver, pancreas, and spleen were calculated. Qualitative and quantitative parameters were compared between the SD-IR, LD-IR, and LD-DLIR images. The CT dose-index volumes (CTDI_vol) and dose-length product (DLP) were compared between SD and LD scans.Results:The image quality and lesion detection rate of the LD-DLIR was comparable to the SD-IR. The image quality was significantly better in SD-IR than in LD-IR (p < 0.017). The attenuation values of all anatomical structures were comparable between the SD-IR and LD-DLIR (p = 0.28–0.96). However, background noise was significantly lower in the LD-DLIR (p < 0.001) and resulted in improved SNRs (p < 0.001) compared to the SD-IR and LD-IR images. The mean CTDI_vol and DLP were significantly lower in the LD (2.9 mGy and 216.2 mGy•cm) than in the SD (13.5 mGy and 1011.6 mGy•cm) (p < 0.0001).Conclusion:LD CT images reconstructed with DLIR enable radiation dose reduction of >75% while maintaining image quality and lesion detection rate and superior SNR in comparison to SD-IR.Advances in knowledge:Deep learning image reconstruction algorithm enables around 80% reduction in radiation dose while maintaining the image quality and lesion detection compared to standard-dose whole-body CT.